Anti-AT1R autoantibodies and prediction of the severity of Covid-19

Hum Immunol. 2022 Feb;83(2):130-133. doi: 10.1016/j.humimm.2021.10.006. Epub 2021 Nov 10.

Abstract

The stimulation of AT1R (Angiotensin II Receptor Type 1) by Angiotensin II has, in addition to the effects on the renin-angiotensin system, also pro-inflammatory effects through stimulation of ADAM17 and subsequent production of INF-gamma and Interleukin-6. This pro-inflammatory action stimulate the cytokine storm that characterizes the most severe forms of SARS-CoV-2 infection. We studied the effect of AT1Rab on the AT1R on 74 subjects with SARS-CoV-2 infection with respiratory symptoms requiring hospitalization. We divided the patients into 2 groups: 34 with moderate and 40 with severe symptoms that required ICU admission. Hospitalized subjects showed a 50% reduction in the frequency of AT1Rab compared to healthy reference population. Of the ICU patients, 33/40 (82.5%) were AT1Rab negative and 16/33 of them (48.5%) died. All 7 patients positive for AT1Rab survived. These preliminary data seem to indicate a protective role played by AT1R autoantibodies on inflammatory activation in SARS-CoV-2 infection pathology.

Keywords: AT1R autoantibodies; Angiotensin II; SARS-CoV-2 infection.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies / immunology*
  • Autoantigens / immunology
  • COVID-19 / immunology*
  • Female
  • Hospitalization
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Receptor, Angiotensin, Type 1 / immunology*
  • Retrospective Studies
  • SARS-CoV-2 / immunology

Substances

  • AGTR1 protein, human
  • Autoantibodies
  • Autoantigens
  • Receptor, Angiotensin, Type 1